Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease

Redox Biology

Volumn 2, Issue 1, 2014, Pages 82-90

  Giordano, Samantha ^a,b   Darley Usmar, Victor ^a,b   Zhang, Jianhua ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Animal models; Anti oxidants; Autophagy; Clinical trials; Mitochondrial dysfunction; Neurons; Parkinson's disease; Protein aggregation; Reactive oxygen species; Redox signaling; Toxins

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CREATINE; PARAQUAT; PLACEBO; RASAGILINE; ROTENONE; SCAVENGER; SELEGILINE; UBIDECARENONE; CATALASE; GLUTATHIONE; MONOAMINE OXIDASE B INHIBITOR; NORPHENAZONE; OXIDOPAMINE; PEROXIREDOXIN; SUPEROXIDE DISMUTASE; TOCOPHEROL; UBIQUINONE; ANTIPARKINSON AGENT; NERVE PROTEIN; NEUROPROTECTIVE AGENT; OXIDOREDUCTASE; PEROXYNITROUS ACID;

ABTS RADICAL SCAVENGING ASSAY; AGING; ANTIOXIDANT ACTIVITY; AUTOPHAGY; CELL ACTIVITY; CELL DAMAGE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE COURSE; DNA DAMAGE; HUMAN; LIPID OXIDATION; LYSOSOME; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; CAUSAL ATTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; LIPID PEROXIDATION; NERVE DEGENERATION; PATHOGENESIS; PROTEIN AGGREGATION; TREATMENT DURATION; ANIMAL; BRAIN; DISEASE MODEL; DRUG SCREENING; METABOLISM; NEURODEGENERATIVE DISEASES; PARKINSONIAN DISORDERS; PATHOLOGY; PHYSIOLOGY;

ANIMALIA;

AGING; ANIMALS; ANTIOXIDANTS; ANTIPARKINSON AGENTS; AUTOPHAGY; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPID PEROXIDATION; LYSOSOMES; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXIDOREDUCTASES; PARKINSONIAN DISORDERS; PEROXYNITROUS ACID;

EID: 84892163616     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.12.013     Document Type: Review

References (133)

1. Dorsey E.R., George B.P., Leff B., Willis A.W. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology 2013, 80:1989-1996.
2. Lee J., Giordano S., Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem. J. 2012, 441:523-540.
3. Hohn A., Grune T. Lipofuscin: formation, effects and role of macroautophagy. Redox Biol. 2013, 1:140-144.
4. Zhang J. Autophagy and mitophagy in cellular damage control. Redox Biol. 2013, 1:19-23.
5. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biol. 2013, 1:244-257.
6. Beckman J.S. Understanding peroxynitrite biochemistry and its potential for treating human diseases. Arch. Biochem. Biophys. 2009, 484:114-116.
7. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87:315-424.
8. Szabo C., Ischiropoulos H., Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 2007, 6:662-680.
9. Tieu K., Ischiropoulos H., Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 2003, 55:329-335.
10. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41:242-247.
11. Brown G.C. Nitric oxide and neuronal death. Nitric. Oxide 2010, 23:153-165.
12. Butterfield D.A., Reed T., Sultana R. Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic. Res. 2011, 45:59-72.
13. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989, 52:381-389.
14. Higdon A., Diers A.R., Oh J.Y., Landar A., rley-Usmar V.M. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem. J. 2012, 442:453-464.
15. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2696-2701.
16. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
17. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 1997, 69:1326-1329.
18. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 2006, 26:5256-5264.
19. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279:13256-13264.
20. Choi J., Sullards M.C., Olzmann J.A., Rees H.D., Weintraub S.T., Bostwick D.E., et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 2006, 281:10816-10824.
21. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.I., Stern M.B., et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 2000, 157:1439-1445.
22. Darley-Usmar V.M., Hogg N., O'Leary V.J., Wilson M.T., Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic. Res. Commun. 1992, 17:9-20.
23. Mecocci P., MacGarvey U., Kaufman A.E., Koontz D., Shoffner J.M., Wallace D.C., et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 1993, 34:609-616.
24. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997, 69:1196-1203.
25. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999, 154:1423-1429.
26. Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 2005, 93:953-962.
27. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr. Rev. 2012, 70:257-265.
28. Raps S.P., Lai J.C., Hertz L., Cooper A.J. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 1989, 493:398-401.
29. Slivka A., Mytilineou C., Cohen G. Histochemical evaluation of glutathione in brain. Brain Res. 1987, 409:275-284.
30. Kang Y., Viswanath V., Jha N., Qiao X., Mo J.Q., Andersen J.K. Brain gamma-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels. J. Neurosci. Res. 1999, 58:436-441.
31. Rebrin I., Kamzalov S., Sohal R.S. Effects of age and caloric restriction on glutathione redox state in mice. Free Radic. Biol. Med. 2003, 35:626-635.
32. Pearce R.K., Owen A., Daniel S., Jenner P., Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 1997, 104:661-677.
33. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36:348-355.
34. Venkateshappa C., Harish G., Mythri R.B., Mahadevan A., Bharath M.M., Shankar S.K. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem. Res. 2012, 37:358-369.
35. Harish G., Mahadevan A., Srinivas Bharath M.M., Shankar S.K. Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson's disease brains. Neurochem. Res. 2013, 38:186-200.
36. Mythri R.B., Venkateshappa C., Harish G., Mahadevan A., Muthane U.B., Yasha T.C., et al. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 2011, 36:1452-1463.
37. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M., Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003, 967:152-160.
38. Werner C.J., Heyny-von H.R., Mall G., Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome. Sci. 2008, 6:8.
39. Paraskevas G.P., Kapaki E., Petropoulou O., Anagnostouli M., Vagenas V., Papageorgiou C. Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism. J. Neurol. Sci. 2003, 215:51-55.
40. Gotz M.E., Gerstner A., Harth R., Dirr A., Janetzky B., Kuhn W., et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J. Neural Transm. 2000, 107:41-48.
41. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 1998, 71:2112-2122.
42. Trinh J., Farrer M. Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 2013.
43. Corti O., Lesage S., Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev. 2011, 91:1161-1218.
44. Byers B., Cord B., Nguyen H.N., Schule B., Fenno L., Lee P.C., et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS ONE 2011, 6:e26159.
45. Su Y.C., Qi X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 2013, 22:4545-4561.
46. Abramov A.Y., Gegg M., Grunewald A., Wood N.W., Klein C., Schapira A.H. Bioenergetic consequences of PINK1 mutations in Parkinson disease. PLoS ONE 2011, 6:e25622.
47. Sanders L.H., Laganiere J., Cooper O., Mak S.K., Vu B.J., Huang Y.A., et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol. Dis. 2013, 62C:381-386.
48. Imaizumi Y., Okada Y., Akamatsu W., Koike M., Kuzumaki N., Hayakawa H., et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain 2012, 5:35.
49. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
50. Dranka B.P., Zielonka J., Kanthasamy A.G., Kalyanaraman B. Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation. J. Neurochem. 2012.
51. Giordano S., Lee J., Darley-Usmar V.M., Zhang J. Distinct Effects of Rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on Cellular Bioenergetics and Cell Death. PLoS ONE 2012, 7:e44610.
52. Mandavilli B.S., Ali S.F., Van H.B. DNA damage in brain mitochondria caused by aging and MPTP treatment. Brain Res. 2000, 885:45-52.
53. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1997, 1362:77-86.
54. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., et al. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 2011, 119:866-872.
55. Marella M., Seo B.B., Nakamaru-Ogiso E., Greenamyre J.T., Matsuno-Yagi A., Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS ONE 2008, 3:e1433.
56. Bashkatova V., Alam M., Vanin A., Schmidt W.J. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp. Neurol. 2004, 186:235-241.
57. Mastroberardino P.G., Hoffman E.K., Horowitz M.P., Betarbet R., Taylor G., Cheng D., et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 2009, 34:417-431.
58. Horowitz M.P., Milanese C., Di M.R., Hu X., Montero L.M., Sanders L.H., et al. Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid. Redox Signal 2011, 15:855-871.
59. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
60. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
61. Fussell K.C., Udasin R.G., Gray J.P., Mishin V., Smith P.J., Heck D.E., et al. Redox cycling and increased oxygen utilization contribute to diquat-induced oxidative stress and cytotoxicity in Chinese hamster ovary cells overexpressing NADPH-cytochrome P450 reductase. Free Radic. Biol. Med. 2011, 50:874-882.
62. Richardson J.R., Quan Y., Sherer T.B., Greenamyre J.T., Miller G.W. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 2005, 88:193-201.
63. Cannon J.R., Greenamyre J.T. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog. Brain Res. 2010, 184:17-33.
64. Liang L.P., Kavanagh T.J., Patel M. Glutathione deficiency in Gclm null mice results in complex I inhibition and dopamine depletion following paraquat administration. Toxicol. Sci. 2013, 134:366-373.
65. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 1993, 18:1175-1177.
66. Kikuchi Y., Yasuhara T., Agari T., Kondo A., Kuramoto S., Kameda M., et al. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. J. Cell Physiol. 2011, 226:1390-1398.
67. Kumar R., Agarwal A.K., Seth P.K. Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 1995, 64:1703-1707.
68. Khan M.M., Ahmad A., Ishrat T., Khan M.B., Hoda M.N., Khuwaja G., et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010, 1328:139-151.
69. Perry T.L., Yong V.W., Clavier R.M., Jones K., Wright J.M., Foulks J.G., et al. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 1985, 60:109-114.
70. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., Yahr M.D. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 1984, 106:209-210.
71. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 1999, 157:142-149.
72. Moussaoui S., Obinu M.C., Daniel N., Reibaud M., Blanchard V., Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 2000, 166:235-245.
73. Horvath T.L., Diano S., Leranth C., Garcia-Segura L.M., Cowley M.A., Shanabrough M., et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology 2003, 144:2757-2760.
74. Levites Y., Weinreb O., Maor G., Youdim M.B., Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 2001, 78:1073-1082.
75. Karunakaran S., Diwakar L., Saeed U., Agarwal V., Ramakrishnan S., Iyengar S., et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J. 2007, 21:2226-2236.
76. Lawler J.M., Barnes W.S., Wu G., Song W., Demaree S. Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. 2002, 290:47-52.
77. Bahat-Stroomza M., Gilgun-Sherki Y., Offen D., Panet H., Saada A., Krool-Galron N., et al. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. Eur. J. Neurosci. 2005, 21:637-646.
78. Kawasaki T., Ishihara K., Ago Y., Baba A., Matsuda T. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J. Pharmacol. Exp. Ther. 2007, 322:274-281.
79. Xiong N., Xiong J., Khare G., Chen C., Huang J., Zhao Y., et al. Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS ONE 2011, 6:e20677.
80. Yuan W.J., Yasuhara T., Shingo T., Muraoka K., Agari T., Kameda M., et al. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci. 2008, 9:75.
81. Clark J., Clore E.L., Zheng K., Adame A., Masliah E., Simon D.K. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS ONE 2010, 5:e12333.
82. 1989. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch. Neurol. 46:1052-1060.
83. Shoulson I. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta Neurol. Scand. 1989, Suppl 126:171-175.
84. 2002. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59:1937-1943.
85. Rascol O., Fitzer-Attas C.J., Hauser R., Jankovic J., Lang A., Langston J.W., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011, 10:415-423.
86. Olanow C.W., Hauser R.A., Jankovic J., Langston W., Lang A., Poewe W., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008, 23:2194-2201.
87. Bender A., Koch W., Elstner M., Schombacher Y., Bender J., Moeschl M., et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006, 67:1262-1264.
88. 2006. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664-671.
89. Elm J.J. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov. Disord. 2012, 27:1513-1521.
90. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 2002, 59:1541-1550.
91. 2007. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20-28.
92. Murphy M.P., Smith R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 2007, 47:629-656.
93. Snow B.J., Rolfe F.L., Lockhart M.M., Frampton C.M., O'Sullivan J.D., Fung V., et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 2010, 25:1670-1674.
94. Jin H., Kanthasamy A., Ghosh A., Anantharam V., Kalyanaraman B., Kanthasamy A.G. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 2013.
95. Kansanen E., Kuosmanen S.M., Leinonen H., Levonen A.L. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1:45-49.
96. Levonen A.L., Landar A., Ramachandran A., Ceaser E.K., Dickinson D.A., Zanoni G., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 2004, 378:373-382.
97. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol. Biochem. 2001, 11:173-186.
98. Yin J.J., Fu P.P., Lutterodt H., Zhou Y.T., Antholine W.E., Wamer W. Dual role of selected antioxidants found in dietary supplements: crossover between anti- and pro-oxidant activities in the presence of copper. J. Agric. Food Chem. 2012, 60:2554-2561.
99. Dodson M., Darley-Usmar V., Zhang J. Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic. Biol. Med. 2013, 63:207-221.
100. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
101. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J.I., Tanida I., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
102. Mortiboys H., Thomas K.J., Koopman W.J., Klaffke S., bou-Sleiman P., Olpin S., et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 2008, 64:555-565.
103. Wang H.L., Chou A.H., Wu A.S., Chen S.Y., Weng Y.H., Kao Y.C., et al. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim. Biophys. Acta 2011, 1812:674-684.
104. Irrcher I., Aleyasin H., Seifert E.L., Hewitt S.J., Chhabra S., Phillips M., et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 2010, 19:3734-3746.
105. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
106. Gandhi S., Wood-Kaczmar A., Yao Z., Plun-Favreau H., Deas E., Klupsch K., et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 2009, 33:627-638.
107. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T.M., Thomas B., et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14807-14812.
108. Guzman J.N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P.T., et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
109. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 2008, 28:10825-10834.
110. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U. S. A 2005, 102:5215-5220.
111. Manning-Bog A.B., Caudle W.M., Perez X.A., Reaney S.H., Paletzki R., Isla M.Z., et al. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol. Dis. 2007, 27:141-150.
112. Pan T., Rawal P., Wu Y., Xie W., Jankovic J., Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 2009, 164:541-551.
113. Xiong N., Jia M., Chen C., Xiong J., Zhang Z., Huang J., et al. Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience 2011, 199:292-302.
114. Sarkar S., Davies J.E., Huang Z., Tunnacliffe A., Rubinsztein D.C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 2007, 282:5641-5652.
115. Fujita K., Maeda D., Xiao Q., Srinivasula S.M. Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1427-1432.
116. Wu Y., Li X., Zhu J.X., Xie W., Le W., Fan Z., et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 2011, 19:163-174.
117. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283:10892-10903.
118. Mahler A., Mandel S., Lorenz M., Ruegg U., Wanker E.E., Boschmann M., et al. Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. EPMA J. 2013, 4:5.
119. Jiang T.F., Zhang Y.J., Zhou H.Y., Wang H.M., Tian L.P., Liu J., et al. Curcumin ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. J. Neuroimmune. Pharmacol. 2013, 8:356-369.
120. Rodriguez-Navarro J.A., Rodriguez L., Casarejos M.J., Solano R.M., Gomez A., Perucho J., et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol. Dis. 2010, 39:423-438.
121. Castillo K., Nassif M., Valenzuela V., Rojas F., Matus S., Mercado G., et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 2013, 9:1308-1320.
122. Du J., Liang Y., Xu F., Sun B., Wang Z. Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice. J. Pharm. Pharmacol. 2013, 65:1753-1756.
123. Ozcelik S., Fraser G., Castets P., Schaeffer V., Skachokova Z., Breu K., et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS ONE 2013, 8:e62459.
124. Malagelada C., Jin Z.H., Jackson-Lewis V., Przedborski S., Greene L.A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 2010, 30:1166-1175.
125. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N.R., Doi H., et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 2004, 10:148-154.
126. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 2009, 29:13578-13588.
127. Decressac M., Mattsson B., Weikop P., Lundblad M., Jakobsson J., Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1817-E1826.
128. Bian M., Liu J., Hong X., Yu M., Huang Y., Sheng Z., et al. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS ONE 2012, 7:e39953.
129. Thomas K.J., McCoy M.K., Blackinton J., Beilina A., van der B.M., Sandebring A., et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet. 2011, 20:40-50.
130. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004, 5:213-218.
131. Miyazaki S., Yanagida T., Nunome K., Ishikawa S., Inden M., Kitamura Y., et al. DJ-1-binding compounds prevent oxidative stress-induced cell death and movement defect in Parkinson's disease model rats. J. Neurochem. 2008, 105:2418-2434.
132. Kitamura Y., Watanabe S., Taguchi M., Takagi K., Kawata T., Takahashi-Niki K., et al. Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model rats. Mol. Neurodegener. 2011, 6:48.
133. Jeong H.J., Kim D.W., Woo S.J., Kim H.R., Kim S.M., Jo H.S., et al. Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model. Mol. Cells 2012, 33:471-478.